NASDAQ: CAPR - Capricor Therapeutics, Inc.

Rentabilité sur six mois: -52.73%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Capricor Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).

plus de détails
It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2007-02-13
ISIN US14070B3096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.capricor.com
Цена ао 13.18
Changement de prix par jour: +3.14% (9.4)
Changement de prix par semaine: +11.44% (8.7)
Changement de prix par mois: -26.72% (13.23)
Changement de prix sur 3 mois: -22.99% (12.59)
Changement de prix sur six mois: -52.73% (20.51)
Changement de prix par an: +65.44% (5.86)
Evolution du prix sur 3 ans: +174.65% (3.53)
Evolution du prix sur 5 ans: +765.63% (1.12)
Evolution des prix depuis le début de l'année: -50.64% (19.64)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 4.73 3
P/BV 5.27 2
P/E 0 0
EV/EBITDA -4.78 0
Total: 4.38

Efficacité

Nom Signification Grade
ROA, % -37.95 0
ROE, % -98.61 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.2439 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 2417.81 10
Rentabilité Ebitda, % 194.99 10
Rentabilité EPS, % -58.18 0
Total: 8
Plus de détails

Établissements Volume Partager, %
Vanguard Group Inc 1165404 3.7
Woodline Partners LP 909542 2.89
Blackrock Inc. 359673 1.14
Geode Capital Management, LLC 316198 1
Susquehanna International Group, LLP 149115 0.47
Renaissance Technologies, LLC 146321 0.46
Northern Trust Corporation 127229 0.4
Osaic Holdings Inc 116550 0.37
State Street Corporation 85224 0.27
Bank Of New York Mellon Corporation 84759 0.27



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 120k 1956 (69 années)
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 280.62k 1963 (62 année)
Mr. Anthony J. Bergmann M.B.A. CFO & Corporate Treasurer 437k 1986 (39 années)
Ms. Karen G. Krasney Executive VP, General Counsel & Secretary 426.72k 1953 (72 année)
Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer N/A
Catherine Lee Kelleher Consultant N/A

Adresse: United States, San Diego. CA, 10865 Road to the Cure - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.capricor.com